Myszkowski Kenneth Allen

Chief Financial Officer | CFO

1 company

Strong

Trades Analyzed

12M Win Rate

71.4%

Avg 3M Return

+33.5%

Avg 12M Return

-2.3%

Myszkowski Kenneth Allen is a Chief Financial Officer at ARROWHEAD PHARMACEUTICALS, INC.. Recent SEC Form 4 filings include 0 buys and 22 sells.

Estimated insider holdings value: $38.1M based on current market prices.

Holdings by Company

ARWRJan 7, 2025

Current Shares465.4K

Value$38.13M

Net Activity-669,053

Bought: 0Sold: 669.1K

Showing 10 filings

Date	Ticker	Role	Type	Shares	Price	Value	Chg%	3M	12M
Jan 7, 2025	ARWR Arrowhead Pharmaceuticals, Inc.	Chief Financial Officer	Sell	45,167	$19.77	$893,095.40	-2.3%	-47.9%	+234.0%
Mar 6, 2024	ARWR Arrowhead Pharmaceuticals, Inc.	Chief Financial Officer	Sell	40,000	$35.19	$1,407,600.00	-9.1%	-28.6%	-50.1%
Jan 5, 2024	ARWR Arrowhead Pharmaceuticals, Inc.	Chief Financial Officer	Sell	16,104	$35.27	$567,909.60	-1.2%	-26.7%	-44.4%
Jun 27, 2023	ARWR Arrowhead Pharmaceuticals, Inc.	Chief Financial Officer	Sell	15,000	$36.20	$543,000.00	-3.8%	-26.1%	-27.2%
Dec 29, 2022	ARWR Arrowhead Pharmaceuticals, Inc.	Chief Financial Officer	Sell	30,625	$40.00	$1,225,000.00	-8.3%	-38.3%	-23.7%
Jan 5, 2022	ARWR Arrowhead Pharmaceuticals, Inc.	Chief Financial Officer	Sell	40,000	$61.70	$2,467,940.96	-2.1%	-19.6%	-38.4%
Jan 12, 2021	ARWR Arrowhead Pharmaceuticals, Inc.	Chief Financial Officer	Sell	13,038	$81.02	$1,056,309.94	-1.4%	-	-
Jan 6, 2021	ARWR Arrowhead Pharmaceuticals, Inc.	Chief Financial Officer	Sell	30,625	$72.44	$2,218,477.01	-2.1%	-	-
Nov 9, 2020	ARWR Arrowhead Pharmaceuticals, Inc.	Chief Financial Officer	Sale+OE	43,505	$69.37	$3,018,070.50	-4.7%	-	-
Oct 20, 2020	ARWR Arrowhead Pharmaceuticals, Inc.	Chief Financial Officer	Sale+OE	29,166	$54.04	$1,576,130.64	-6.4%	-	-